Skip to Content
Merck
All Photos(1)

Key Documents

11484281001

Roche

BM Blue POD Substrate, soluble

solution (ready-to-use), suitable for ELISA, pkg of 100 mL

Synonym(s):

3,3′,5,5′-Tetramethylbenzidine solution

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H20N2
CAS Number:
Molecular Weight:
240.34
Beilstein:
2808541
MDL number:
UNSPSC Code:
12352204
PubChem Substance ID:

description

3,3′-5,5′-Tetramethylbenzidine (TMB)

Quality Level

form

solution (ready-to-use)

mol wt

Mr 240.35

packaging

pkg of 100 mL

manufacturer/tradename

Roche

technique(s)

ELISA: suitable

solubility

water: soluble

storage temp.

2-8°C

SMILES string

Cc1cc(cc(C)c1N)-c2cc(C)c(N)c(C)c2

InChI

1S/C16H20N2/c1-9-5-13(6-10(2)15(9)17)14-7-11(3)16(18)12(4)8-14/h5-8H,17-18H2,1-4H3

InChI key

UAIUNKRWKOVEES-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Application

BM Blue POD Substrate, soluble, is ideal for ELISA applications. It has been used in fluorescein-tagged exendin-4 binding assay.

Specifications

Formula: C16H20N2
Color: blue; yellow after reaction is stopped
Evaluation: photometric (450 nm)

Physical form

Solution, ready-to-use

Analysis Note

Absorption: Identical to TMB absorption spectrum

Other Notes

For life science research only. Not for use in diagnostic procedures.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

No data available

Flash Point(C)

No data available


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kuan-Ying A Huang et al.
PLoS pathogens, 17(2), e1009352-e1009352 (2021-02-27)
Serological and plasmablast responses and plasmablast-derived IgG monoclonal antibodies (MAbs) have been analysed in three COVID-19 patients with different clinical severities. Potent humoral responses were detected within 3 weeks of onset of illness in all patients and the serological titre
Daming Zhou et al.
Nature structural & molecular biology, 27(10), 950-958 (2020-08-02)
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with
Sindhu Rajan et al.
Molecular metabolism, 4(4), 265-276 (2015-04-02)
Glucagon-like peptide 1 (GLP-1) enhances insulin secretion and protects β-cell mass. Diabetes therapies targeting the GLP-1 receptor (GLP-1R), expressed in numerous tissues, have diminished dose-response in patients with type 2 diabetes compared with healthy human controls. The aim of this
Jiandong Huo et al.
Nature structural & molecular biology, 27(9), 846-854 (2020-07-15)
The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a more serious illness than influenza. The SARS-CoV-2 receptor binding domain (RBD) of the spike protein binds to the human angiotensin-converting enzyme 2 (ACE2) receptor as a prelude to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service